CD274 and ovarian carcinoma: In a phase II study of pembrolizumab (anti-PD-1) in 376 women with platinum-resistant ovarian cancer (1–6 prior lines), the ORR was 8.0% (7 CRs, 23 PRs) with DCR of 37.2%, but response may be higher in those with high PD-L1 expression (18% ORR in those with >10% expression) [8•].